UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of October 2023

Commission File Number: 001-38097

ARGENX SE

(Translation of registrant's name into English)

Laarderhoogtweg 25
1101 EB Amsterdam, the Netherlands
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

argenx SE

On October 31, 2023, argenx SE (the "Company) issued a press release and investor presentation, copies of which are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference herein.

The information contained in this Current Report on Form 6-K, including the exhibits hereto, is incorporated by reference into the Company's Registration Statements on Forms F-3 (File No. 333-258251 and S-8 (File Nos. 333-225375, 333-258253 and 333-274721).

EXHIBITS

Exhibit	Description
99.1	Press Release dated October 31, 2023
99.2	Investor Presentation dated October 31, 2023

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ARGENX SE

Date: October 31, 2023

By: /s/ Hemamalini (Malini) Moorthy
Hemamalini (Malini) Moorthy
General Counsel

Exhibit 99.1

argenx Reports Third Quarter 2023 Financial Results and Provides Business Update

- $329 million in third quarter global net product sales
- On track to submit VYVGART® Hytrulo sBLA for CIDP by year-end 2023
- Results from the ADVANCE-IV study published in *The Lancet*
- Management to host conference call today at 1:30 pm CET (8:30 am ET)

October 31, 2023

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2023 financial results and provided a business update and outlook for the remainder of the year.

"We continue to prioritize patient impact with VYVGART and VYVGART Hytrulo, broadening our two gMG products into earlier treatment lines and new geographies. VYVGART has now been used in thousands of patients over multiple treatment years, and its unique clinical profile has built patient trust and physician confidence in the brand," said Tim Van Hauwermeiren, Chief Executive Officer of argenx. "There is a significant opportunity before us to transform autoimmunity across multiple indications with VYVGART. Based on the successful ADHERE trial, we are ready to file the sBLA by the end of 2023 to bring our first-in-class FcRn blocker to CIDP patients as quickly as possible. We are also on track with two near-term pivotal readouts and an ambitious plan forward over the coming years as we continue to execute and drive innovation within our FcRn portfolio and across immunology more broadly."

THIRD QUARTER 2023 AND RECENT BUSINESS UPDATE

VYVGART Expansion

VYVGART® is a first-in-class antibody fragment targeting the neonatal Fc receptor (FcRn) and is now approved globally in seven countries or regions (U.S., Japan, EU, UK, Israel, China, Canada) for generalized myasthenia gravis (gMG). VYVGART Hytrulo (subcutaneous (SC) injection) was approved in the U.S. in June 2023. argenx is planning for multi-dimensional expansion to reach more patients with gMG and other severe autoimmune diseases through additional global regulatory approvals.

- Generated global net product revenues (inclusive of both VYVGART and VYVGART Hytrulo) of $329 million in the third quarter of 2023
- Health Canada approved VYVGART on September 21, 2023, marking the seventh global approval for gMG

- European Commission (EC) approval of SC efgartigimod for gMG expected in fourth quarter of 2023 following positive recommendation from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)
- Japan approval decision regarding SC efgartigimod for gMG expected by first quarter of 2024
- Japan marketing authorization application (MAA) filed for VYVGART for primary immune thrombocytopenia (ITP); approval decision expected in first quarter of 2024
- U.S. supplemental Biologics License Application (sBLA) for VYVGART Hytrulo in chronic inflammatory demyelinating polyneuropathy (CIDP) on track to be filed by end of 2023
- China approval decision regarding SC efgartigimod for gMG expected by end of 2024 through partnership with Zai Lab

Efgartigimod Research and Development

argenx is solidifying its leadership in FcRn blockade and demonstrating the broad potential of efgartigimod by advancing its clinical development programs of IgG-mediated autoimmune diseases. By 2025, efgartigimod is expected to be approved, in regulatory review or in development in 15 severe autoimmune diseases

- Topline data from ADVANCE-SC (ITP) expected in fourth quarter of 2023; results from ADVANCE-IV study were published in *The Lancet* in September 2023
- Topline data from ADDRESS (pemphigus) and GO/NO GO decision from BALLAD (bullous pemphigoid) both expected around year-end 2023
- GO/NO GO decision expected from ALKIVIA (myositis) in second half of 2024
- Topline data from ALPHA (post-COVID postural orthostatic tachycardia syndrome (PC-POTS)) expected in first quarter of 2024 and RHO (Sjogren's syndrome) in first half of 2024

Pipeline Progress

argenx is advancing a robust portfolio of innovative clinical programs, including empasiprubart (C2 inhibitor) and ARGX-119 (muscle-specific kinase (MuSK) agonist). Both programs have the potential to be first-in-class opportunities for multiple severe indications.

- Topline data from Phase 2 ARDA study of empasiprubart (ARGX-117) in multifocal motor neuropathy (MMN) expected in 2024
- Phase 1 study of ARGX-119 ongoing in healthy volunteers; subsequent Phase 1b trial planned to assess early signal detection in patients with congenital myasthenic syndrome (CMS) and amyotrophic lateral sclerosis (ALS)

Immunology Innovation Program

argenx continues to invest in its discovery engine, the Immunology Innovation Program, to foster a robust innovation ecosystem and drive early-stage pipeline growth. argenx expects to nominate one new pipeline candidate in 2023.

argenx SE

UNAUDITED CONDENSED CONSOLIDATED INTERIM STATEMENTS OF PROFIT OR LOSS

	Three Months Ended September 30,		Nine Months Ended September 30,	
(in thousands of $ except for shares and EPS)	**2023**	**2022**	**2023**	**2022**
Product net sales	$ 329,097	$ 131,329	$ 816,432	$ 227,325
Collaboration revenue	692	6,652	3,047	9,262
Other operating income	10,050	8,508	31,275	26,565
Total operating income	**$ 339,839**	**$ 146,489**	**$ 850,754**	**$ 263,152**
Cost of sales	$ (35,999)	$ (10,264)	$ (78,358)	$ (16,646)
Research and development expenses	(191,755)	(236,681)	(553,119)	(515,568)
Selling, general and administrative expenses	(191,930)	(108,181)	(503,079)	(336,845)
Loss from investment in joint venture	(743)	-	(2,623)	-
Total operating expenses	**(420,427)**	**(355,126)**	**(1,137,179)**	**(869,059)**
Operating loss	**$ (80,588)**	**$ (208,637)**	**$ (286,425)**	**$ (605,907)**
Financial income	$ 30,049	$ 8,007	$ 67,078	$ 13,740
Financial expense	(231)	(785)	(626)	(2,916)
Exchange gains/(losses)	(32,509)	(39,609)	(23,345)	(92,991)
Loss for the period before taxes	**$ (83,279)**	**$ (241,024)**	**$ (243,318)**	**$ (688,074)**
Income tax (expense)/benefit	$ 10,637	$ 5,982	$ 47,437	$ 17,096
Loss for the period	**$ (72,642)**	**$ (235,042)**	**$ (195,881)**	**$ (670,978)**
Loss for the year attributable to:				
Owners of the parent	$ (72,642)	$ (235,042)	$ (195,881)	$ (670,978)
Weighted average number of shares outstanding	58,128,233	55,203,655	56,512,254	54,049,119
Basis and diluted loss per share (in $)	(1.25)	(4.26)	(3.47)	(12.41)
Net increase/(decrease) in cash, cash equivalents and current financial assets compared to year-end 2022 and 2021			$ 993,035	$ 48,813
Cash and cash equivalents and current financial assets at the end of the period			$ 3,185,583	$ 2,385,541

DETAILS OF THE FINANCIAL RESULTS

Total operating income for the third quarter and year-to-date in 2023 was $339.8 million and $850.8 million, respectively, compared to $146.5 million and $263.2 million for the same periods in 2022, and mainly consists of:

- **Product net sales** of VYVGART for the three months ended and nine months ended September 30, 2023, were $329.1 million and $816.4 million, compared to $131.3 million and $227.3 million for the same periods in 2022.
- **Other operating income** for the third quarter and year-to-date in 2023 was $10.1 million and $31.3 million, respectively, compared to $8.5 million, and $26.6 million for the same periods in 2022. The other operating income for the three and nine months ended September 30, 2023, primarily relates to research and development tax incentives and payroll tax rebates. Other income also includes $0.7 million in royalty revenue from VYVGART sales in China.

Total operating expenses for the third quarter and year-to-date in 2023 were $420.4 million and $1,137.2 million, respectively, compared to $335.1 million and $869.1 million for the same periods in 2022, and mainly consists of:

- **Cost of sales** for the third quarter and year-to-date in 2023 was $36.0 million and $78.4 million, respectively, compared to $10.3 million and $16.6 million for the same periods in 2022. The cost of sales was recognized with respect to the sale of VYVGART and VYVGART Hytrulo.
- **Research and development expenses** for the third quarter and year-to-date in 2023 were $191.8 million and $553.1 million, respectively, compared to $236.7 million and $515.6 million for the same periods in 2022. The research and development expenses mainly relate to external research and development expenses and personnel expenses incurred in the clinical development of efgartigimod in various indications and the expansion of other clinical and preclinical pipeline candidates.
- **Selling, general and administrative expenses** for the third quarter and year-to-date in 2023 were $191.9 million and $503.1 million, respectively, compared to $108.2 million and $336.8 million for the same periods in 2022. The selling, general and administrative expenses mainly relate to professional and marketing fees linked to the commercialization of VYVGART and VYVGART Hytrulo in the U.S., EU and Japan, and personnel expenses.

Financial income for the third quarter and year-to-date in 2023 was $30.0 million and $67.1 million, respectively, compared to $8.0 million and $13.7 million for the same periods in 2022. The increase in financial income is mainly due to an increase in interest income on current financial assets and cash and cash equivalents attributable to higher interest rates.

Exchange losses for the third quarter and year-to-date in 2023 were $32.5 million and $23.3 million respectively, compared to $39.6 million and $93.0 million of exchange losses for the same periods in 2022. Exchange gains/losses are mainly attributable to unrealized exchange rate gains or losses on the cash, cash equivalents and current financial assets position in Euro.

Income tax for the third quarter and year-to-date in 2023 was $10.6 million and $47.4 million of tax benefit, respectively, compared to $6.0 million and $17.1 million of tax benefit for the same periods in 2022. Tax benefit for the nine months ended September 30, 2023, consists of $23.8 million of income tax expense and $71.3 million of deferred tax income, compared to $15.0 million of income tax expense and $32.1 million of deferred tax income for the comparable prior period.

Net loss for the three and nine-month periods ended September 30, 2023, was $72.6 million and $195.9 million, respectively, compared to $235.0 million and $671.0 million over the prior year periods. On a per weighted average share basis, the net loss was $3.47 and $12.41 for the nine months ended September 30, 2023 and 2022, respectively.

Cash, cash equivalents and current financial assets totalled $3.2 billion as of September 30, 2023, compared to $2.2 billion as of December 31, 2022. The increase in cash and cash equivalents and current financial assets resulted primarily from the closing of a global offering of shares, including a U.S. offering, which resulted in the receipt of $1.2 billion in net proceeds in July 2023, partially offset by net cash flows used in operating activities.

EXPECTED 2024 FINANCIAL CALENDAR

- February 29, 2024: FY 2023 financial results and business update
- May 9, 2024: Q1 2024 financial results and business update
- July 25, 2024: Q2 2024 financial results and business update
- October 24, 2024: Q3 2024 financial results and business update

CONFERENCE CALL DETAILS

The third quarter 2023 financial results and business update will be discussed during a conference call and webcast presentation today at 1:30 pm CET/8:30 am ET. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website.

Dial-in numbers:

Please dial in 15 minutes prior to the live call.

Belgium	32 800 50 201
France	33 800 943355
Netherlands	31 20 795 1090
United Kingdom	44 800 358 0970
United States	1 888 415 4250
Japan	81 3 4578 9081
Switzerland	41 43 210 11 32

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Twitter, and Instagram.

For further information, please contact:

Media:
Erin Murphy
emurphy@argenx.com

Investors:
Alexandra Roy (US)
aroy@argenx.com

Lynn Elton (EU)
lelton@argenx.com

Forward-looking Statements

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes," "hope," "estimates," "anticipates," "expects," "intends," "may," "will," or "should" and include statements argenx makes regarding its plans to execute and drive innovation within its FcRn portfolio and across immunology; its plans for multi-dimensional expansion to reach more patients with gMG and other autoimmune diseases through additional global regulatory approvals; advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the (1) expected EC approval of SC efgartigimod for gMG in the fourth quarter of 2023, (2) expected approval decision regarding SC efgartigimod for gMG in Japan by the first quarter of 2024, (3) expected MAA for VYVGART for primary ITP approval decision in Japan in the first quarter of 2024, (4) expected filing of the sBLA for VYVGART Hytrulo in CIDP by the end of 2023, (5) expected approval decision regarding SC efgartigimod for gMG in China by end of 2024 through its partnership with Zai Lab; (6) expected topline data from ITP in the fourth quarter of 2023, (7) expected topline data from ADDRESS and the GO/NO GO decision from BALLAD around year-end 2023, (8) expected GO/NO GO decision from ALKIVIA in the second half of 2024, (9) expected topline dtaa from ALPHA in the first quarter of 2024 and RHO in the first half of 2024, (10) expected topline data from Phase 2 ARDA study of ARGX-117 in MMN in 2024, (11) planned Phase 1b trial to assess early signal detection in patients with CMS and ALS and (12) planned nomination of a new pipeline candidate in 2023; continued investment in its Immunology Innovation Program to foster a robust innovation ecosystem and drive early-stage pipeline growth; and 2023 business and financial outlook and related plans, the timeline of future releases of financial results and business updates. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including inflation and deflation and the corresponding fluctuations in interest rate; regional instability and conflicts, such as the conflict between Russia and Ukraine, argenx's expectations regarding the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx's reliance on collaborations with third parties; estimating the commercial potential of argenx's product candidates; argenx's ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx's limited operating history; and argenx's ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.

argenx

Together We Discover

Third Quarter 2023 Financial Results and Business Update

October 31, 2023

Forward Looking Statements

This presentation has been prepared by argenx se ("argenx" or the "company") for informational purposes only and not for any other purpose. Nothing contained in this presentati should be construed as, a recommendation, promise or representation by the presenter or the company or any director, employee, agent, or adviser of the company. This presenta not purport to be all-inclusive or to contain all of the information you may desire. Certain information contained in this presentation relates to or is based on studies, publications, s other data obtained from third-party sources and the company's own internal estimates and research. While argenx believes these third-party studies, publications, surveys and oth be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any informa obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of argenx's internal estimates or research and no reliance shou made on any information or statements made in this presentation relating to or based on such internal estimates and research.

The contents of this presentation include statements that are, or may be deemed to be, "forward-looking statements." These forward-looking statements can be identified by the u forward-looking terminology, including the terms "believes," "hope," "estimates," "anticipates," "expects," "intends," "may," "will," or "should" and include statements argenx make its launch of VYVGART for generalized myasthenia gravis (gMG) and expansion strategy to reach more patients with VYVGART through additional regulatory approvals; the safety pr efficacy of VYVGART, the advancement of ARGX-117 and ARGX-119 to clinical proof-of-concept; the planned SC approval and June 20th PDUFA date; its ability to transform gMG tre patients; its anticipated clinical data readouts, including in chronic inflammatory demyelinating polyneuropathy (CIDP), immune thrombocytopenia (ITP), pemphigus vulgaris (PV), p orthostatic tachycardia syndrome (POTS) and multifocal motor neuropathy (MMN); the therapeutic potential and patient treatment experience of its product candidates, its strateg expand access to treatments through engagement with physicians, payors, and patient communities; expected filing of the sBLA for VYVGART Hytrulo in CIDP by the end of 2023; p regulatory reviews of SC efgartigimod for gMG in China, Canada, Europe, and Japan; expectations about its pipeline progress; its collaborations and their potential benefits; the inte results of its strategy and its collaboration partners', advancement of, and anticipated clinical development, data readouts and regulatory milestones and plans, including the timing planned clinical trials and expected data readouts; the design of future clinical trials and the timing and outcome of regulatory filings and regulatory approvals; and its 2023 busines financial outlook and related plans. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements guarantees of future performance. argenx's actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, incl effects of the COVID-19 pandemic, inflation and deflation and the corresponding fluctuations in interest rates; regional instability and conflicts, such as the conflict between Russia Ukraine, argenx's expectations regarding the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and approval requirements; argenx's reliance on collaborations with third parties; estimating the commercial potential of argenx's product candidates; argenx's ability to obtain and ma protection of intellectual property for its technologies and drugs; argenx's limited operating history; and argenx's ability to obtain additional funding for operations and to complete development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx's U.S. Securities and Commission (SEC) filings and reports, including in argenx's most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with t Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date o publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as required by law.


Driving Sustained Growth Across the Business
Consistent Execution + Perpetual Innovation
Reaching More Patients
Geographic Expansion
Pioneer FcRn Class of Medicines
Broaden Immunology Pipeline
Double-digit growth quarter over quarter
Approval in Canada
Filing of CIDP sBLA by EOY
GO decision in MMN

What FcRn Leadership Looks Like Today

20 presentations demonstrating neuromuscular leadership

AANEM
American Association of Neuromuscular & Electrodiagnostic Medicine

mg MYASTHENIA GRAVIS FOUNDATION OF AMERICA
For a World Without Myasthenia Gravis

>1,000 Patient Years
of safety data across indications

Real-world experience in
~6,000 patients

Favorable Safety
TEAEs mild to moderate

Consistent Efficacy
MG-ADL, QMG, QoL, MSE

Deep FcRn Expertise
Unique target modulation

arge

ITP ADVANCE-SC Trial



Primary endpoint: Sustained platelet count (≥50×10^9/L) in ≥4/6 visits between weeks 19 and 24

Stringent endpoint in line with regulatory feedback, addressing platelet count variability

Secondary and exploratory endpoints center around extent of disease control to illustrate real-world viability

Topline data expected **4Q 2023**

q2w = every other week

Pemphigus ADDRESS Trial:



Topline data expected around YE 2023

CR=complete clinical remission; CRmin=complete remission on minimal therapy; EoC=end of consolidation; SC=subcutaneous.

Steady Cadence of Upcoming Data Readouts

advance	ITP-SC: Topline data expected in 4Q 2023
address	Pemphigus: Topline data expected around year-end 2023
ballad	Bullous Pemphigoid (BP): GO/NO GO decision expected around year-end 2023
alpha	Post-COVID Postural Orthostatic Tachycardia Syndrome (PC-POTS): Topline data expected in 1Q 2024
rho STUDY	Sjogren's Syndrome: Topline data expected in first half 2024
alkivia	Myositis: GO/NO GO decision expected in second half of 2024
arda	Multifocal Motor Neuropathy (MMN): Topline data from Phase 2 (empasiprubart) expected in 2024

Third Quarter 2023 Finance Summary

Q3 2023 Product Net Sales of $329M

Product Net Sales by Region

(in millions of $)	Q3 2023	Q2 2023	QoQ % Growth
US	280	244	+15%
Japan	15	13	+15%
EMEA	26	12	+128%
China	7	-	n/a
Total	**329**	**269**	**+22%**

Table in $'m and impacted by rounding.

Summary P/L

(in millions of $)	Three months ended September 30		Nine months ended September 30	
	2023	**2022**	**2023**	**2022**
Product net sales	329	131	816	227
Other & collaboration rev	11	15	34	36
Total operating income	340	146	851	263
Total operating expenses	(420)	(355)	(1,137)	(869
Operating loss for the period	(81)	(209)	(286)	(606
Financial inc / (exp)	(3)	(32)	43	(82)
Loss before tax	(83)	(241)	(243)	(688
Tax	11	6	47	17
Loss for the period	(73)	(235)	(196)	(671

Total Operating Expenses include Cost of Sales, R&D, SG&A and Loss from investment in joint venture.
Financial income / (expenses) includes financial income / (expenses) and exchange gains / (losses).
Table in $'m and impacted by rounding.

Ended third quarter 2023 with cash of $3.2B

Cash reflects cash, cash equivalents and current financial assets.

arge


Multi-dimensional Expansion to Reach Autoimmune Patients Globa
Presentations
Future presentations
Pre-filled syringe
VYVGART Hytrulo
VYVGART
gMG
CIDP
ITP
Pemphigus
BP
Myositis
POTS
Sjogren's
15 indications by 2025
Indications
Geographies
US
Japan
EMEA
UK
China
Canada
Future geographies

Optimizing Core Launch Strategies

Hytrulo launch driven by VYVGART-naïve patients

Reaching Broader gMG Population

Hytrulo contributing to expansion

Continued shift into earlier lines

Driving brand loyalty among prescribers

88% of key target prescribers reached since launch

First Hytrulo policies published

Policies in line with IV

arge

Innovating on the Patient Experience

Future product presentations providing flexibility in HOW and WHERE patients are treated

Today

1

VYVGART® Hytrulo

(efgartigimod alfa and hyaluronidase-qvfc)

Subcutaneous Injection
180 mg/mL and 2000 U/mL vial

Single 30-90 second Injection

Effective

Safe

Future

2 **Second Generation**

- Pre-filled Syringe (PFS)
- Ongoing development in BE/HF studies
- Aim to support self-administration[1]

More details early next year

3 **Future Generations**

- Exclusive collaboration Halozyme
- Collaboration on formulation elektrofi
- Exploring autoinjector and additional formats to optimize patient experience

arge

Note: Self administration expected on label in Europe and Japan


Reaching gMG Patients Across the Globe
VYVGART®
APPROVALS COMPLETE
U.S. DEC 2021
JAPAN JAN 2022
EUROPE SEPT 2022
UK MAR 2023
ISRAEL APRIL 2023
CHINA JUNE 2023
CANADA SEPT 2023
VYVGART® Hytrulo
APPROVALS COMPLETE
U.S. JUNE 202
APPROVALS PENDING
JAPAN BY Q1 20
EUROPE Q4 2023
CHINA 2024
arge

Advancing Hytrulo in CIDP

adhere
chronic inflammatory demyelinating polyneuropathy study

First Innovation in 30+ Years

Potential new treatment modality

Bringing Hope to Patients of New Treatment Option

99% rollover into OLE

Crystal
Living With CIDP

I was the type of woman that would run first thing in the morning before work, and then CIDP hit, and it was like hitting the wall at a hundred miles an hour.

Unlocking New Disease Biology Insights

IgG shown to play **significant role** in underlying biology of CIDP

Largest Global CIDP Trial

New standard set for innovative trial design

On track to file sBLA in 2023 with launch targeted in 2024

arge


Our mission
continues...
Co-Creation
Empowerment
argenx
Innovation
Excellence
Humility